vs

Side-by-side financial comparison of John Marshall Bancorp, Inc. (JMSB) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.

John Marshall Bancorp, Inc. is the larger business by last-quarter revenue ($16.8M vs $8.6M, roughly 2.0× Sunshine Biopharma Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -25.0%, a 61.3% gap on every dollar of revenue. Over the past eight quarters, John Marshall Bancorp, Inc.'s revenue compounded faster (15.3% CAGR vs 6.6%).

John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.

Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.

JMSB vs SBFM — Head-to-Head

Bigger by revenue
JMSB
JMSB
2.0× larger
JMSB
$16.8M
$8.6M
SBFM
Higher net margin
JMSB
JMSB
61.3% more per $
JMSB
36.3%
-25.0%
SBFM
Faster 2-yr revenue CAGR
JMSB
JMSB
Annualised
JMSB
15.3%
6.6%
SBFM

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
JMSB
JMSB
SBFM
SBFM
Revenue
$16.8M
$8.6M
Net Profit
$6.1M
$-2.1M
Gross Margin
35.3%
Operating Margin
-20.9%
Net Margin
36.3%
-25.0%
Revenue YoY
-10.6%
Net Profit YoY
26.8%
0.8%
EPS (diluted)
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JMSB
JMSB
SBFM
SBFM
Q1 26
$16.8M
Q4 25
$16.4M
$8.6M
Q3 25
$16.3M
$9.4M
Q2 25
$15.4M
$9.4M
Q1 25
$14.6M
$8.9M
Q4 24
$14.3M
$9.6M
Q3 24
$13.8M
$8.4M
Q2 24
$12.6M
$9.3M
Net Profit
JMSB
JMSB
SBFM
SBFM
Q1 26
$6.1M
Q4 25
$5.9M
$-2.1M
Q3 25
$5.4M
$-883.8K
Q2 25
$5.1M
$-1.8M
Q1 25
$4.8M
$-1.2M
Q4 24
$4.8M
$-2.2M
Q3 24
$4.2M
$-1.2M
Q2 24
$3.9M
$-494.3K
Gross Margin
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
35.3%
Q3 25
32.6%
Q2 25
36.4%
Q1 25
30.7%
Q4 24
32.2%
Q3 24
34.0%
Q2 24
25.3%
Operating Margin
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
47.4%
-20.9%
Q3 25
42.2%
-11.5%
Q2 25
42.7%
-21.8%
Q1 25
42.4%
-14.6%
Q4 24
42.5%
-21.7%
Q3 24
38.8%
-13.1%
Q2 24
39.7%
-13.6%
Net Margin
JMSB
JMSB
SBFM
SBFM
Q1 26
36.3%
Q4 25
36.2%
-25.0%
Q3 25
33.2%
-9.4%
Q2 25
33.1%
-18.8%
Q1 25
32.9%
-13.3%
Q4 24
33.3%
-22.5%
Q3 24
30.7%
-14.2%
Q2 24
30.9%
-5.3%
EPS (diluted)
JMSB
JMSB
SBFM
SBFM
Q1 26
$0.43
Q4 25
$0.41
Q3 25
$0.38
$-0.54
Q2 25
$0.36
$-0.82
Q1 25
$0.34
$-0.44
Q4 24
$0.33
$49.77
Q3 24
$0.30
$-11.61
Q2 24
$0.27
$-43.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JMSB
JMSB
SBFM
SBFM
Cash + ST InvestmentsLiquidity on hand
$150.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$268.1M
$23.0M
Total Assets
$2.4B
$30.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JMSB
JMSB
SBFM
SBFM
Q1 26
$150.2M
Q4 25
$130.0M
Q3 25
$163.6M
Q2 25
$116.9M
Q1 25
$169.1M
Q4 24
$122.5M
Q3 24
$177.2M
Q2 24
$182.6M
Total Debt
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
$80.9M
Q3 25
$80.9M
Q2 25
$80.8M
Q1 25
$80.8M
Q4 24
$80.8M
Q3 24
$80.8M
Q2 24
$24.7M
Stockholders' Equity
JMSB
JMSB
SBFM
SBFM
Q1 26
$268.1M
Q4 25
$265.6M
$23.0M
Q3 25
$259.7M
$24.2M
Q2 25
$253.7M
$25.7M
Q1 25
$253.0M
$22.7M
Q4 24
$246.6M
$23.5M
Q3 24
$243.1M
$25.0M
Q2 24
$235.3M
$23.5M
Total Assets
JMSB
JMSB
SBFM
SBFM
Q1 26
$2.4B
Q4 25
$2.3B
$30.1M
Q3 25
$2.3B
$31.5M
Q2 25
$2.3B
$32.0M
Q1 25
$2.3B
$29.2M
Q4 24
$2.2B
$30.6M
Q3 24
$2.3B
$30.1M
Q2 24
$2.3B
$29.3M
Debt / Equity
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
0.30×
Q3 25
0.31×
Q2 25
0.32×
Q1 25
0.32×
Q4 24
0.33×
Q3 24
0.33×
Q2 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JMSB
JMSB
SBFM
SBFM
Operating Cash FlowLast quarter
$-1.6M
Free Cash FlowOCF − Capex
$-1.6M
FCF MarginFCF / Revenue
-18.9%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
$22.6M
$-1.6M
Q3 25
$1.2M
$-727.8K
Q2 25
$7.5M
$-1.3M
Q1 25
$7.0M
$-1.7M
Q4 24
$17.3M
$-3.4M
Q3 24
$1.4M
$-1.4M
Q2 24
$10.2M
$-4.6M
Free Cash Flow
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
$22.0M
$-1.6M
Q3 25
$1.2M
$-735.8K
Q2 25
$7.4M
$-1.4M
Q1 25
$6.6M
$-1.7M
Q4 24
$16.8M
$-3.5M
Q3 24
$1.3M
$-1.9M
Q2 24
$10.1M
$-5.6M
FCF Margin
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
134.7%
-18.9%
Q3 25
7.3%
-7.8%
Q2 25
47.8%
-15.2%
Q1 25
45.3%
-19.3%
Q4 24
116.9%
-36.6%
Q3 24
9.5%
-22.2%
Q2 24
80.1%
-59.7%
Capex Intensity
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
3.4%
0.0%
Q3 25
0.2%
0.1%
Q2 25
1.0%
1.7%
Q1 25
2.3%
0.1%
Q4 24
3.4%
1.1%
Q3 24
0.8%
6.1%
Q2 24
0.4%
10.5%
Cash Conversion
JMSB
JMSB
SBFM
SBFM
Q1 26
Q4 25
3.82×
Q3 25
0.23×
Q2 25
1.48×
Q1 25
1.45×
Q4 24
3.61×
Q3 24
0.33×
Q2 24
2.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JMSB
JMSB

Net Interest Income$16.5M98%
Noninterest Income$284.0K2%

SBFM
SBFM

Segment breakdown not available.

Related Comparisons